ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1893

Substantial Structural Lesions on MRI in the Sacroiliac Joints of Patients with Non-Radiographic Axial Spondyloarthritis Even in the Absence of MRI Inflammation

Walter P. Maksymowych1, S Wichuk1, H Jones2, A Szumski3, L Marshall4, J Bukowski5 and RG Lambert6, 1Department of Medicine, University of Alberta, Edmonton, AB, Canada, 2Inflammation & Immunology, Pfizer Inc., Collegeville, PA, 3Specialty Care, Pfizer Inc., Collegeville, PA, 4Inflammation Immunology Disease Group, Pfizer Inc., Collegeville, PA, 5Pfizer Inc., Collegeville, PA, 6Radiology, University of Alberta, Edmonton, AB, Canada

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: axial spondyloarthritis, etanercept and inflammation, Lesions, MRI

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Imaging of Rheumatic Diseases: X-ray, MRI and CT

Session Type: Abstract Submissions (ACR)

Background/Purpose: Treatment of axial SpA is increasingly aimed at intervention early in the disease course before radiographic sacroiliitis has appeared and when response to treatment is greatest. If radiographs do not indicate sacroiliitis, the Assessment of SpondyloArthritis (ASAS) classification criteria indicate that bone marrow edema (BME)/osteitis on MRI is a requirement, but this may also occur non-specifically, and some patients lack MRI inflammation. The purpose of this analysis was to assess the relative importance of structural lesions on MRI in the sacroiliac joints (SIJ) of patients with non-radiographic axial SpA (nr-axSpA).

Methods: Patients had axial SpA per the ASAS classification criteria, but did not meet modified NY radiographic criteria. Patients had symptoms for >3 months and <5 years, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) ≥4, and failed ≥2 NSAIDs. Patients were randomly assigned to etanercept 50 mg/week or placebo, then after 12 weeks, all patients received open-label etanercept 50 mg/week. Clinical and health outcomes were assessed throughout the study, and MRI of the SIJ and spine was performed by two central readers at baseline, weeks 12 and 48 to assess BME using the Spondyloarthritis Research Consortium of Canada (SPARCC) score. Additionally, a post-hoc analysis was conducted to score structural lesions using the SPARCC SIJ structural method, which assesses fat metaplasia, erosion, backfill, and ankylosis on T1-weighted spin echo (T1WSE) MRI. Two independent readers scored baseline and 48 week T1WSE MRI scans from 187 cases blinded to patients and short tau inversion recovery (STIR) MRI scans. Mean scores of the readers were used. SPARCC SIJ BME score ≥2 was used as the operational definition of positive MRI evidence of inflammation. For these analyses, all patients were combined, independent of randomization.

Results: Mean (SD) age was 32 (7.8) years, 60.5% were male, and mean (SD) duration of disease symptoms was 2.5 (1.8) years. A total of 73% of patients were human leukocyte antigen B27 (HLA-B27) positive and 81% met the ASAS MRI imaging criteria at baseline. Additionally, 61% had a structural lesion on MRI at baseline comprised of erosion (58%), backfill (23%), fat metaplasia (18%), and ankylosis (7%). Of the patients who were ASAS MRI positive, 65% had a structural lesion on MRI, compared to 43% who were ASAS MRI negative. Of the patients with SPARCC SIJ BME score ≥2 at baseline, 79% had a structural lesion on MRI compared to 35% with SPARCC SIJ BME score <2.  Relative frequencies of MRI structural lesions in patients with SPARCC SIJ BME ≥2 vs <2 were: erosions (78% vs 30%), backfill (36% vs 5%), fat (22% vs 13%), and ankylosis (7% vs 7%).

Conclusion: Structural lesions on MRI occur frequently in nr-axSpA despite the absence of radiographic sacroiliitis and even in the absence of MRI inflammation. This finding strongly reinforces the concept of nr-axSpA as an early stage of axial SpA.     


Disclosure:

W. P. Maksymowych,

Pfizer Inc,

2,

Pfizer Inc,

5;

S. Wichuk,
None;

H. Jones,

Pfizer Inc,

3,

Pfizer Inc,

1;

A. Szumski,

Pfizer Inc,

5;

L. Marshall,

Pfizer Inc,

1,

Pfizer Inc,

3;

J. Bukowski,

Pfizer Inc,

1,

Pfizer Inc,

3;

R. Lambert,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/substantial-structural-lesions-on-mri-in-the-sacroiliac-joints-of-patients-with-non-radiographic-axial-spondyloarthritis-even-in-the-absence-of-mri-inflammation/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology